Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
MDxHealth Miljarden Strijdtoneel
Volgen
Billionaire Battleground: Exact Sciences Inc. Billionaire investors have been buying and selling millions of shares of Exact Sciences stock recently. Here's a look at the bull and bear case. Cologuard Kit Sourceexactsciences IMAGE SOURCE: EXACT SCIENCES. Every few months the SEC requires billionaire investors to publicly disclose their holdings using a form called a 13F. These filings are filled with intellectual gold and are a great way for individual investors to follow what some of the smartest investors in the world have been buying and selling recently. One company that has become a battleground stock among billionaires recently is Exact Sciences (NASDAQ:EXAS), a money-losing healthcare company that is focused on noninvasive cancer detection. The company's shares have had an awful year, and are down more than 75% due to slower-than-hoped-for sales of its noninvasive colon cancer detection test, Cologuard. Several billionaire investors have greatly soured on the company's stock, including Israel Englander, the hedge fund manager of Millennium Management. This fund's recent filing showed that it sold more than 1.7 million shares of Exact Sciences stock. On the other hand, Exact Sciences' falling share price has also attracted the attention of billionaire buyers, including David Shaw, the founder of D.E. Shaw & Co. Shaw's fund recently added more than 1.3 million shares of the Exact Sciences stock to its portfolio. So what's going on at Exact Sciences that has left billionaire investors divided on the company's future? Here's the case for, and against, investing in Exact Sciences stock right now. The bull case Bulls point out that Cologuard was designed to fix a big problem with colon cancer detection, namely that very few patients actually follow current screening guidelines. Exact Sciences likes to point out that only three out of every 1,000 patients currently adhere to annual fecal blood testing guidelines over a 10-year period, which is a horrifically low rate. Boxes Sourceexactsciences IMAGE SOURCE: EXACT SCIENCES. Exact Sciences Cologuard system has been shown to make huge strides in fixing this problem. Last quarter Cologuard's compliance rate was 69%, a massive improvement. Increasing compliance rates is important since patients stand a much better chance at beating colon cancer if the disease is detected early. Still, Cologuard sales were slow out of the gate, which is a big reason why the company's stock has tanked. Management believes that Cologuard's lackluster start is caused by a lack of insurance coverage and low awareness among providers. In order to address these issues, Exact Sciences has been laser-focused on getting more payers on board. The company recently convinced Anthem (NYSE:ANTM) to add Cologuard to its formulary, which is a huge win since Anthem already has nearly 40 million members under its umbrella. That number will also take a giant leap forward later this year if Anthem's pending acquisition of Cigna is closed. The odds look good of that happening since Anthem recently received regulatory clearance in 12 states and from 99% of both Cigna and Anthem's shareholders. With Anthem signed on it and Cigna joining the picture, Exact Sciences should have an easier time convincing other insurers to follow suit. To help get the word out about Cologuard, management recently announced an ambitious marketing plan that includes a nationwide television campaign. Early testing showed a doubling of new physicians' prescriptions from TV ads, which hints that this strategy might actually work. Finally, bulls are banking on the company's ability to expand its technology beyond just colon cancer. Exact Sciences is currently exploring ways to use its technology to detect both pancreatic and lung cancer, and it is also working on a new version of Cologuard that should greatly enhance its margins. With better coverage on the way and awareness building, management believes that the company will process more than 240,000 Cologuard tests this year and produce $90 million to $100 million in revenue. That's more than double what it produced in 2015. If the company can deliver on that target and continue to expand into other types of cancer, shares could dramatically rise from here. The bear case Of course, while the prospects of amazing growth and margin expansion sound great, the company's bears have plenty of points to make as well. For one, Cologuard is primarily targeted at seniors, which means that Exact Sciences' pricing will forever hinge on Medicare's reimbursement policies. Given that general healthcare inflation has been out of control for years, policymakers eventually may lean on companies like Exact Sciences to drop prices over time. In that case, the company's long-term profitability may come into question. Exas Fb IMAGE SOURCE: EXACT SCIENCES. Another concern is that while compliance for using Cologuard is much better than traditional methods, it's still far from perfect. After all, a compliance rate of 69% means that almost one out of three patients are ordering the system and then not following through with the actual testing. That represents a cost to the company that is not turning into revenue, which is a huge drag on the company's margins. Finally, bears point out that the company is going to have to significantly increase its spending in order to fund its marketing plan, which is going to be very costly. While revenue is expected to jump to $90 million to $100 million this year, losses will balloon too. Wall Street is currently estimating that the company will lose about $2 in earnings per share this year, which translates into roughly $190 million. That's a sizable chunk of the company's $262 million cash hoard, and could hint that yet another round of dilution could be on the way. Looking ahead With billionaires divided about whether this company is a buy or a sell, the smart play might be to watch its results for another few quarters before deciding which way to lean. The other thing to keep in mind is that the intentions behind billionaires' buys and sells may be very different from yours, and following blindly in their footsteps is never a good idea. My take: While I think that Cologuard is a fascinating product that offers a great option to patients and providers, I have some big concerns about the company's long-term profitability. For that reason I'm content to keep watching this story unfold from the sidelines. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here.www.fool.com/investing/2016/05/28/bil...
ok faire analyse en glas is half vol of half leeg. in ieder geval zal het langer duren
IRVINE, Calif. and HERSTAL, Belgium, June 14, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first U.S. reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with America's Choice Provider Network, Inc. (ACPN). ACPN is a national provider network with over 1,700 payers, including insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans, providing coverage to 24 million American lives and 750,000 international lives. "We are pleased to sign this agreement with ACPN just 3 months after we have launched our SelectMDx test on the U.S. market," said Dr. Jan Groen, CEO of MDxHealth. "Our investment last year into the company's managed care team has already been producing results and we continue to build strong relationships with payors across the country." globenewswire.com/news-release/2016/0...
Ga je dan ook weer een apart TomTom draadje openen?
With better coverage on the way and awareness building, management believes that the company will process more than 240,000 Cologuard tests this year and produce $90 million to $100 million in revenue.
inspirator schreef op 14 juni 2016 17:13 :
With better coverage on the way and awareness building, management believes that the company will process more than 240,000 Cologuard tests this year and produce $90 million to $100 million in revenue.
Wat zit je nu te bazelen. Dit gaat over Exas. MDX krijgt wat royalties mooi meegenomen. Hebben ze ook hard nodig. Maar er is al sprake geweest van ontkoppeling...
inspirator schreef op 14 juni 2016 08:10 :
IRVINE, Calif. and HERSTAL, Belgium, June 14, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first U.S. reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with America's Choice Provider Network, Inc. (ACPN). ACPN is a national provider network with over 1,700 payers, including insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans, providing coverage to 24 million American lives and 750,000 international lives.
"We are pleased to sign this agreement with ACPN just 3 months after we have launched our SelectMDx test on the U.S. market," said Dr. Jan Groen, CEO of MDxHealth. "Our investment last year into the company's managed care team has already been producing results and we continue to build strong relationships with payors across the country."
globenewswire.com/news-release/2016/0... MdxHealth is zich aan het herpakken: Omzet van hun produkten stijgt explosief.
inspirator schreef op 14 juni 2016 18:04 :
[...]
MdxHealth is zich aan het herpakken:
Omzet van hun produkten stijgt explosief.
Waar baseer je dat op?
MdxHealth spreidt zijn veugels uit over de miljardenmarkt. Fantastische presentatie vandaag in New York
MDXHealth - Piggybacking On Exact Sciences' Cologuard Success If the market valuation of Exact Sciences is anywhere close to reflecting future sales of Cologuard, shares of MDXHealth should double, triple or more. Net present value estimates of only the Cologuard royalty stream for MDXHealth range between EUR 4.57 and EUR 15, while MDXHealth shares are currently at EUR 3.014. Buying into the Cologuard royalty stream at a discount also gets you MDXHealth's own potential cash cows ConfirmMDX, SelectMDX!and AssureMDX for free.
MDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk June 15, 2016 01:07 ET | Source: MdxHealth (TM) IRVINE, Calif. and HERSTAL, Belgium, June 15, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR), announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure assay to determine cervical cancer risk. Under the terms of the agreement, QIAGEN has licensed the use of MDxHealth's MSP technology, a proprietary DNA-methylation specific PCR methodology, for the development and commercialization of its new diagnostic test which differentiates patients' risk of developing cervical cancer. MDxHealth will receive a signing fee plus royalties from future test sales utilizing this technology. QIAGEN reported that the QIAsure test is a highly complementary addition to its leading human papilloma virus (HPV) franchise. Women screening positive for HPV, or with abnormal cells identified by cytology, are at increased risk of developing cervical cancer. The QIAsure test is the next logical step to assess this risk. More information about the QIAsure product launch can be found at: QIAGEN launches QIAsure Methylation Test to determine cervical cancer risk. "We are pleased that our Methylation technology can further support QIAGEN's efforts to improve women's health," stated Dr. Jan Groen, CEO of MDxHealth. "Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528,000 new cases diagnosed and 266,000 deaths each year, so clearly this is an important test." About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at www.qiagen.com. About MDxHealth MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
ik vraag me af wat onze adviseur Lorteenhoop ervan vindt. Als hij ook positief is vergroot ik mijn positie.
Zeer goed nieuws en Qiagen is een zeer groet speler.
limomilo schreef op 15 juni 2016 10:30 :
ik vraag me af wat onze adviseur Lorteenhoop ervan vindt. Als hij ook positief is vergroot ik mijn positie.
Lordopeenhoop is meer voor de downswing....www.youtube.com/watch?v=tdXLfUJdae0
Teveel en onnodig veel naar beneden gegaan de afgelopen weken. Lord heeft daardoor wel gelijk gekregen, helaas. Maar goed, zijn visie deelt hij niet of hij werkt voor MdX en weet meer (lijkt me niet), of hij werkt voor de concurrent, of hij houdt ervan mensen te irriteren en ligt elke keer weer dubbel als we hem om zijn advies vragen.
21 juni overname MdxHealth door Exact Sciences een feit Exact Sciences: What the Heck is Going On? By Ben Levisohn Yesterday, shares of Exact Sciences (EXAS) surged for no reason at all. Today, they’re up another 7%–and we now know the reason for the stock’s big move. Canaccord Genuity’s Mark Massaro and Mary Kate Gorman explain: We reiterate our BUY rating on Exact Sciences and raise our PT to $12 from $9. Around 10 pm ET or so on Tuesday (June 14), the USPSTF uploaded a 12-page recommendation statement that we believe bodes well for Exact Sciences. In the document, the USPSTF removed the words “recommended” and “alternative” and reiterated that “colorectal cancer screening” is an A rating, and clearly removed any hierarchy of test modalities. We spoke late last night with management, which is declining comment until the USPSTF formally announces these statements (press release) or when JAMA publishes these findings (June 21 on the Task Force document). We’ll let events play out over the next few days before we update out-year revenue estimates. Our raised PT to $12 now uses a 6.0x multiple on our unchanged 2018 revenue estimate of $250M, discounted back to the present at a 15% discount rate. Our view is that this is long-awaited great news for Exact Sciences, a decision we believe will trigger commercial payor mandates, notably from UnitedHealth Group (UNH) and Aetna (AET), to name two. The next key controversy likely turns to at what price the large payors will pay for Cologuard. Remember, shares of Exact Sciences lost nearly half their value back in October after it was originally designated an “alternative.”
Het wordt een beetje een een grijsgedraaide plaat maar waar lees jij nu dat Exas MDX gaat overnemen?
New Colorectal Cancer Screening Guidelines From USPSTF May Benefit Exact Sciences' Cologuard Said very clearly, this clarification places Cologuard on par with other screening strategies and makes it an 'A' rated test for individuals age 50-75," Weinstein added. "We expect this will have material impact on reimbursement discussions as the Affordable Care Act requires all 'A' rated screening tests to be covered without co-pay. In addition, we believe this will place Cologuard into quality metrics like HEDIS and Star, which should also push insurance coverage across the goal line."www.genomeweb.com/molecular-diagnosti...
Short squeeze MdxHealth aanstaande MDxHealth Announces European Urology Editorial Supporting SelectMDx Use in Detecting Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM - June 16, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today the publication of an editorial in the prestigious journal European Urology that supports the integration of SelectMDxTM liquid biopsy test results into established clinical algorithms to improve the detection of high-risk prostate cancer (PCa) [Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer, Gardiner et al, European Urology (2016)].
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee